Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA:688806)

China · Delayed Price · Currency is CNY

23.04

-1.18 (-4.87%)

At close: Sep 4, 2026

Market Cap	10.61B
Revenue (ttm)	116.93M +240.2%
Net Income	-510.54M
EPS	-1.31
Shares Out	460.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,389,113
Open	24.49
Previous Close	24.22
Day's Range	22.91 - 25.53
52-Week Range	14.46 - 52.52
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 25, 2026

About SHA:688806

Zhuhai Trinomab Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, and commercializes therapeutics for infectious diseases and pain-related or autoimmune disorders. The company’s product includes Siltartoxatug Injection (TNM002), a recombinant anti-tetanus toxin monoclonal antibody that neutralizes the toxic effects that target the human neural system. The company was founded in 2015 and is based in Zhuhai, China. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2015

Employees 843

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688806

Full Company Profile

Financial Performance

In 2025, SHA:688806's revenue was 51.22 million, an increase of 240.23% compared to the previous year's 15.06 million. Losses were -601.32 million, 16.8% more than in 2024.

Financial Statements